SCM
MNPR icon

Sterling Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Sterling Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59K Hold
29
– – ﹤0.01% 3032
2025
Q4 		$1.89K Buy
29
+20
+222% +$1.63K ﹤0.01% 3074
2025
Q3 		$735 Sell
9
-1
-10% -$45 ﹤0.01% 3122
2025
Q2 		$358 Buy
+10
New +$363 ﹤0.01% 3191

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sterling Capital Management's MNPR Position: Q1 2026 in Review

Sterling Capital Management held its Monopar Therapeutics (MNPR) position steady in Q1 2026 at 29 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #3032.

Sterling Capital Management first reported a position in MNPR in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.89K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Sterling Capital Management held 29 shares of Monopar Therapeutics worth $1.59K as of Q1 2026.
  • Sterling Capital Management left its Monopar Therapeutics share count unchanged in Q1 2026.
  • Monopar Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3032 holding.
  • Sterling Capital Management first reported a position in Monopar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Sterling Capital Management's Monopar Therapeutics position peaked at $1.89K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.